首页> 美国卫生研究院文献>Antibiotics >Promising Antibiofilm Agents: Recent Breakthrough against Biofilm Producing Methicillin-Resistant
【2h】

Promising Antibiofilm Agents: Recent Breakthrough against Biofilm Producing Methicillin-Resistant

机译:有前途的抗血栓药:近期对生物膜产生耐药抗性的突破

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Multidrug resistant (MDR) methicillin-resistant Staphylococcus aureus (MRSA) is a superbug pathogen that causes serious diseases. One of the main reasons for the lack of the effectiveness of antibiotic therapy against infections caused by this resistant pathogen is the recalcitrant nature of MRSA biofilms, which results in an increasingly serious situation worldwide. Consequently, the development of innovative biofilm inhibitors is urgently needed to control the biofilm formation by this pathogen. In this work, we thus sought to evaluate the biofilm inhibiting ability of some promising antibiofilm agents such as zinc oxide nanoparticles (Zno NPs), proteinase K, and hamamelitannin (HAM) in managing the MRSA biofilms. Different phenotypic and genotypic methods were used to identify the biofilm producing MDR MRSA isolates and the antibiofilm/antimicrobial activities of the used promising agents. Our study demonstrated strong antibiofilm activities of ZnO NPs, proteinase K, and HAM against MRSA biofilms along with their transcriptional modulation of biofilm (intercellular adhesion A, icaA) and quorum sensing (QS) (agr) genes. Interestingly, only ZnO NPs showed a powerful antimicrobial activity against this pathogen. Collectively, we observed overall positive correlations between the biofilm production and the antimicrobial resistance/agr genotypes II and IV. Meanwhile, there was no significant correlation between the toxin genes and the biofilm production. The ZnO NPs were recommended to be used alone as potent antimicrobial and antibiofilm agents against MDR MRSA and their biofilm-associated diseases. On the other hand, proteinase-K and HAM can be co-administrated with other antimicrobial agents to manage such types of infections.
机译:多药抗性(MDR)耐甲氧胞苷葡萄球菌(MRSA)是一种卓越的病原体,导致严重疾病。缺乏这种抗性病原体引起的抗生素治疗有效性的主要原因之一是MRSA生物膜的顽固性质,这导致全世界越来越严重的情况。因此,迫切需要通过该病原体控制创新的生物膜抑制剂的发展来控制生物膜形成。在这项工作中,我们试图评估一些有前途的抗生素(如氧化锌纳米粒子(ZnO NPS),蛋白酶K和HamameLitannin(Ham)在管理MRSA生物膜中的生物膜抑制能力。使用不同的表型和基因型方法来鉴定生物膜产生MDR MRSA分离物和使用过的有前途的药剂的抗菌剂/抗微生物活性。我们的研究证明了ZnO NPS,蛋白酶K和火腿的强烈抗生素活性,以及​​它们对MRSA生物膜的转录调节以及对群(细胞间粘附A,ICAA)和法定感测(AGR)基因的转录调节。有趣的是,只有ZnO NPS对该病原体表现出强烈的抗微生物活性。统称,我们观察了生物膜生产与抗微生物抗性/农业基因型II和IV之间的总体正相关性。同时,毒素基因与生物膜生产之间没有显着相关性。建议ZnO NPS单独使用,作为针对MDR MRSA及其生物膜相关疾病的有效抗微生物和抗菌剂药剂。另一方面,蛋白酶-K和火腿可以与其他抗微生物剂共同施用以管理这种类型的感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号